355P - First report of long-term responders to first-line bevacizumab (BEV) combined with chemotherapy in two independent cohorts of HER2-neg metastatic br...

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Anticancer agents
Breast Cancer
Biological therapy
Presenter Mahasti Saghatchian
Authors M. Saghatchian1, C. Levy2, C.B. Villanueva3, J. Fleury4, V. Dieras5, A. Mercier-Blas6, H. Simon7, C. Le Maignan8, E. Antoine9, N. Mesnard10
  • 1Breast Cancer Unit, Department Of Medical Oncology, Institut de Canc, FR-94805 - Villejuif CEDEX/FR
  • 2Sénologie, Centre François BACLESSE, Caen/FR
  • 3Service Oncologie Medicale, C.H.U. Jean Minjoz, FR-25030 - Besancon CEDEX/FR
  • 4Oncologie, Pole Santé République, Clermont Ferrand/FR
  • 5Department Of Medical Oncology, Clinical Trial Unit, Institut Curie, 75005 - Paris/FR
  • 6Oncologie, Centre de Radiothérapie Saint-Vincent, Saint-Grégoire/FR
  • 7Oncologie Médicale, Hôpital Augustin Morvan, Brest/FR
  • 8Oncologie Médicale, Hôpital Saint-Louis, Paris/FR
  • 9Oncologie Médicale, Clinique Hartmann, Neuilly-Sur-Seine/FR
  • 10Medical Affair, Roche SAS, Boulogne Billancourt/FR



First-line BEV combined with weekly paclitaxel, docetaxel or other chemotherapy significantly improves progression-free survival (PFS) in HER2-negative metastatic breast cancer (mBC), as shown in E2100, AVADO and RIBBON-1 trials. In the ATHENA study, 21% of pts continued BEV for ≥1 year with no new safety outcome and a time to progression of 19.9 months (95% CI 18.9-21.8 months). To further understand and provide insight into the efficacy and safety of long-term responders to first-line BEV, we conducted a descriptive study of 2 different cohorts of pts with mBC: HR+ and TN, treated in routine oncology practice with at least 1 year of first-line BEV.


Pts who had received first-line BEV(≥1 year) associated to chemotherapy were retrospectively included in the 2 independent cohorts and followed up, if they were alive at inclusion, for 18 months. Clinico-pathological characteristics, treatment received, efficacy and safety data were collected.


The recruitment of the TNBC cohort was just completed (n = 80) and results will be presented at the meeting. In the HR+ cohort (n = 132), 28.1% of the pts had a disease-free interval <12 months, 46.7% had >3 metastatic sites at diagnosis, and more than 1/3 of the patient had lung and/or liver involvement. In association to 1st line BEV, 93,2% had received a taxane as initial 1st line chemotherapy, 76.2% had received maintenance endocrine therapy and 4.2% had received maintenance chemotherapy (capecitabine). Best response obtained in 1st line was a complete response or partial response for 84,6%. With a median follow-up of 33 months, median PFS was 27.4 months (95% CI [23.2-33.8]). Overall survival data were immature as 84.8% of the pts were alive at inclusion. The most common BEV related grade 3/4 adverse events were hypertension (7.5%), bleeding (1.9%), proteinuria (1.3%) and congestive heart failure (1.3%).


Prolonged BEV-containing therapy in this HR+ cohort is of interest and suggests that some pts achieve sustained disease control with limited side effects.


V. Diéras: Advisory boards and Symposium participation.

H. Simon: Member of an advisory board: Roche Mastology Group.

N. Mesnard: Roche employee.

E. Antoine: Membership of an advisory board.

All other authors have declared no conflicts of interest.